Skip to main content

Table 1 Summary of on-market FDA-approved PD-L1 IHC scoring algorithms and associated testing assays

From: Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring

  1. This summary is for on-market PMA-approved PD-L1 IHC companion and complementary diagnostic tests and their associated scoring algorithms. Tests are companion diagnostics unless otherwise noted as complementary diagnostics
  2. FDA United States Food and Drug Administration, IC Immune cells, IHC Immunohistochemistry, PD-L1 Programmed death-ligand 1, PMA Premarket approval, TC Tumor cells
Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us